Abstract:Introduction: The members retinoic acid receptors (RARs) (α, β, and γ) and retinoid X receptors (RXRs) (α, β, and γ) belong to the retinoid receptor family. They regulate the biological action of classical retinoids through nuclear retinoid receptors, a transcription factor that is regulated by ligands. Through the binding of particular retinoic acid-responsive elements (RAREs) located in target gene promoters, RARs and members of the RXRs form heterodimers. By binding to its nuclear receptors and triggering the transcription of the target genes downstream, retinoic acid (RA) mediates the expression of certain genes. Retinoids so mainly control gene expression to carry out their biological actions. RARs are essential for many biological processes, such as development, immunity, reproduction, organogenesis, and homeostasis. Apart from their physiological functions, RARs are also linked to pathologies and tumors due to mutations, protein fusions, changes in expression levels, or abnormal post-translational changes that lead to aberrant functions and homeostasis breakdown. The oncogenic development of animal tissues or cultured cells is linked to altered expression of retinoid receptors. The RAR-α is over-expressed in several malignancies. Increased invasion and migration in several cancer forms, including HNSC carcinoma, pediatric low-grade gliomas, lung adenocarcinoma, and breast cancer, have been linked to its upregulated expression. Numerous approved therapeutic regimens targeting RAR-α have been developed, improving patient survival rates. Objective: This study's main objective was to identify novel RAR-α-targeting drugs and evaluate the expression patterns of RAR-α in breast cancer patients. Methodology: In-silico investigation using a variety of bioinformatics tools like UALCAN, TISCH, TIMER 2.0, ENRICHR, and others were employed to examine the expression of RAR-α. Further we evaluated in-silico inhibition of RAR-α with trifarotene and also tested the cytotoxicity of trifarotene in breast cancer cells. Results: Our research indicates that RAR-α is upregulated in several malignancies including Breast Cancer. It regulates granulocyte differentiation and has an association with the retinoic acid receptor signaling pathway and cellular response to estrogen stimulus. Furthermore, trifarotene was found as a potential synthetic compound that targets RAR-α through in silico and in-vitro study. Discussion: Overall, this research indicates that elevated expression of RAR-α enhances the onset of breast cancer. Using trifarotene medication to target RAR-α will significantly boost the response of breast cancer individuals to treatment and delay the development of resistance to drugs.

Retinoic Acid Nuclear Receptor Α (rarα), a Major Role in Mediating Retinoids Inhibition of Growth in Human Breast Carcinoma Cells

Retinoid-resistant Estrogen Receptor-Negative Human Breast Carcinoma Cells Transfected with Retinoic Acid Receptor-Alpha Acquire Sensitivity to Growth Inhibition by Retinoids.

Expression of Nuclear Retinoid Receptors in Normal, Premalignant and Malignant Gastric Tissues Determined by in Situ Hybridization

Expression of the Retinoic Acid Receptors (rars) and Retinoid X Receptor (rxrs) Genes in Breast Cancer

[Retinoic Acid Nuclear Receptor Beta (RAR Beta) Inhibits Breast Carcinoma Growth].

Elevated Expression of Retinoic Acid Receptor-Alpha (rar Alpha) in Estrogen-Receptor-Positive Breast Carcinomas As Detected by Immunohistochemistry

The Pathophysiological Roles and Regulatory Mechanism of Retinoic Acid Receptor-related Orphan Receptors

Molecular Recognition of CYP26A1 Binding Pockets and Structure–activity Relationship Studies for Design of Potent and Selective Retinoic Acid Metabolism Blocking Agents

Identification of Retinoic Acid As an Inhibitor of Transcription Factor Nrf2 Through Activation of Retinoic Acid Receptor Alpha

Structural Basis for Retinoic X Receptor Repression on the Tetramer

Rexinoid Inhibits Nrf2-Mediated Transcription Through Retinoid X Receptor Alpha

The retinoid X receptor has a critical role in synthetic rexinoid-induced increase in cellular all- trans -retinoic acid

Loss of CAK phosphorylation of RAR{alpha} mediates transcriptional control of retinoid-induced cancer cell differentiation.

RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2.

Retinoid-dependent in vitro transcription mediated by the RXR/RAR heterodimer.

Altered RBP1 Gene Expression Impacts Epithelial Cell Retinoic Acid, Proliferation, and Microenvironment

Identification of influential proteins in the classical retinoic acid signaling pathway

Exploring the role of trifarotene against RAR-α: an investigation of expression pattern and clinicopathological significance of RAR-α in breast cancer

Targeting Expression of a Dominant-Negative Retinoic Acid Receptor Mutant in the Epidermis of Transgenic Mice Results in Loss of Barrier Function.

N-(4-Hydroxyphenyl)Retinamide (4-Hpr)-mediated Biological Actions Involve Retinoid Receptor-Independent Pathways in Human Breast-Carcinoma

Retinoic Acid and Estrogen Modulation of Insulin-like Growth Factor Binding Protein-4 Gene Expression and the Estrogen Receptor Status of Human Breast Carcinoma Cells